FDA officials explained that a different control strategy is needed to demonstrate drug quality for solid oral drugs made by continuous mode than batch mode, reflecting the very different nature of these manufacturing processes.
FDA is attempting to clear up some of the ambiguities associated with continuous manufacturing, and this pronouncement reflects the agency’s evolving stance on continuous manufacturing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?